Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 8935 results

  1. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

    In development Reference number: GID-TA11733 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  4. Surgical mesh for treatment of primary ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

    Health technology evaluations
    In development

  5. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  6. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]

    Awaiting development Reference number: GID-TA11969 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  12. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    20 December 2016

  14. Antimicrobial prescribing: meropenem with vaborbactam (ES21)

    Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making

    Evidence summary
    Published
    20 November 2019

  15. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

    Evidence summary
    Published
    18 December 2019